What are the treatment strategies for an infant (1–12 months) with extensively drug‑resistant Acinetobacter baumannii that is only susceptible to aminoglycosides?

Treatment of Extensively Drug-Resistant Acinetobacter baumannii (Aminoglycoside-Only Susceptible) in Infants

For an infant with extensively drug-resistant Acinetobacter baumannii susceptible only to aminoglycosides, use combination therapy with an aminoglycoside (gentamicin or amikacin) plus colistin, even if colistin susceptibility is uncertain, as monotherapy with aminoglycosides alone is inadequate for serious infections.

Recommended Treatment Regimen

Primary Combination Therapy

Aminoglycoside Selection and Dosing 1:

For infants 1-12 months:

• Gentamicin: 2.5 mg/kg IV every 8 hours (conventional dosing) OR 5-7.5 mg/kg IV every 24 hours (once-daily dosing)
• Amikacin: 15 mg/kg IV every 24 hours (once-daily dosing preferred)

Plus Colistin 1:

• IV Colistin: 2.5-5 mg CBA/kg/day IV divided in 2-4 doses
• Maximum: 100 mg CBA/dose

Critical Rationale for Combination Therapy

Aminoglycosides alone are suboptimal even when the isolate appears susceptible in vitro 2. The 2022 Taiwan MDRO guidelines specifically recommend colistin-based combination therapy for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and pneumonia 1. While your isolate may not be formally tested as colistin-resistant, combination therapy addresses:

• Enhanced bactericidal activity through synergy
• Prevention of resistance emergence during treatment
• Improved clinical outcomes in severe infections

Site-Specific Considerations

For Pneumonia/Ventilator-Associated Pneumonia

• Add nebulized colistin: 2 million IU every 8-12 hours via vibrating plate or ultrasonic nebulizer 3
• Continue IV combination therapy concurrently
• Duration: 10-14 days 1

For Bloodstream Infections

• Duration: 7-14 days, individualized based on source control and clinical response 1
• Ensure removal of any central venous catheters if present 4

For Meningitis/Ventriculitis

• Add intrathecal or intraventricular aminoglycoside 3:
  • Amikacin: 10-50 mg daily IT/IVT
  • Tobramycin: 5-20 mg daily IT/IVT
• Continue IV combination therapy
• Duration: 3 weeks minimum, guided by CSF sterilization 3

Monitoring Requirements

Aminoglycoside Monitoring

• Serum drug levels: Monitor peak and trough concentrations 5, 1
• Renal function: Check creatinine every 2-3 days
• Ototoxicity surveillance: Baseline and periodic hearing assessment if feasible

Clinical Response Assessment

• Daily clinical evaluation for improvement
• Repeat cultures at 48-72 hours to document microbiological clearance
• Adjust therapy if no improvement by day 3-5

Important Caveats and Pitfalls

Why Not Aminoglycoside Monotherapy?

Despite in vitro susceptibility, aminoglycosides penetrate poorly into tissues and have suboptimal bactericidal activity against Acinetobacter when used alone 2, 6. Historical data consistently show treatment failures with monotherapy.

Colistin Considerations

• Even if formal susceptibility testing shows resistance, colistin may still have activity in combination 7
• The 2022 ESCMID guidelines note that polymyxin-carbapenem combinations showed no benefit in large RCTs for CRAB 7, but polymyxin-aminoglycoside combinations are different and supported by observational data 4, 8
• Nephrotoxicity risk is real but manageable with careful monitoring

Alternative if Colistin Unavailable or Contraindicated

• Sulbactam 50 mg/kg/day IV divided in 2-4 doses (maximum 4000 mg/day) 1 plus aminoglycoside
• Sulbactam has intrinsic activity against Acinetobacter 6, 9

Duration of Therapy

• Bloodstream infection: 7-14 days 1
• Pneumonia: 10-14 days 1
• Meningitis: 21 days minimum 3
• Extend duration if slow clinical response or inadequate source control

Infection Control Measures

Given the high transmissibility of XDR Acinetobacter in neonatal/pediatric ICUs 4, 10:

• Contact isolation mandatory
• Cohort infected infants if multiple cases
• Enhanced environmental cleaning
• Limit invasive procedures and duration of mechanical ventilation when possible 4

Prognosis and Expectations

Mortality remains high (up to 50-60%) in infants with XDR Acinetobacter, particularly those <1000g birth weight 4. Factors associated with poor outcome include:

• Septic shock at presentation
• Delayed appropriate therapy
• Immunocompromised status
• Need for mechanical ventilation 11

The key to success is early initiation of appropriate combination therapy, aggressive source control, and meticulous supportive care.